您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (1): 62-67.doi: 10.6040/j.issn.1671-7554.0.2018.890

• 临床医学 • 上一篇    

血清可溶性肿瘤因子2抑制剂、半乳糖凝集素-3蛋白水平在慢性心衰分级及预后中的应用

米传晓1,刘军妮2,邹承伟1,周南南2   

  1. 山东大学附属省立医院 1.心外科;2. 老年心内科, 山东 济南 250021
  • 发布日期:2022-09-27
  • 通讯作者: 周南南. E-mail:1620879003@qq.com
  • 基金资助:
    山东省科技发展计划(2014GGH2018011);山东省医药卫生科技发展计划(2014WS0080;2015BJYB04);2018—2020年国家青年基金(81701385)

Levels of soluble suppression of tumorigenicity 2 and galectin-3 as predictors of the classification and prognosis of chronic heart failure

MI Chuanxiao1, LIU Junni2, ZOU Chengwei1, ZHOU Nannan2   

  1. 1. Department of Cardiac Surgery;
    2. Department of Geriatric Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Published:2022-09-27

PDF (PC)

12

摘要： 目的 通过检测不同纽约心脏病学会心功能分级(NYHA class)下心衰患者血清可溶性肿瘤因子2抑制剂(sST2)和半乳糖凝集素-3(Galectin-3)蛋白水平,明确其在优化心功能分级及预测心衰预后方面的价值。 方法 选取2015年4月至2016年1月山东大学附属省立医院心血管中心住院的心衰患者191例,其中男115例,女76例,40~90岁,平均(62.36±11.09)岁。按NYHA心功能分级(Ⅰ~Ⅳ组)及随访结果分为未发生心脏事件组、心衰恶化组和死亡组,检测入院sST2、galectin-3蛋白水平。每2个月对患者随访1次,记录心脏事件(因心衰恶化再入院或全因死亡)的发生。 结果 血清中sST2、galectin-3蛋白水平与NYHA心功能分级及左心室射血分数(LVEF)的相关性差异有统计学意义,与NYHA心功能分级呈正相关(r1=0.33,P1<0.001;r2=0.21,P2=0.004),与LVEF呈负相关(r1=-0.25,P1=0.001;r2=-0.24,P2=0.002)。血清中sST2、galectin-3蛋白水平在未发生心脏事件组、心衰恶化组、死亡组之间差异均有统计学意义(F1=56.76,P1<0.001;F2=31.08,P2<0.001),未发生心脏事件组与心衰恶化组、未发生心脏事件组与死亡组、心衰恶化组与死亡组血清sST2水平差异均有统计学意义(t1=6.15,P1<0.001;t2=11.36,P2<0.001;t3=3.22,P3=0.003);未发生心脏事件组与心衰恶化组、未发生心脏事件组与死亡组的galectin-3水平差异有统计学意义(t1=6.28,P1<0.001;t2=5.91,P2<0.001)。Galectin-3<15.67 ng/mL、sST2<31.74 ng/mL是心衰患者不发生心脏事件的预测因子;sST2>45.031 ng/mL是心衰患者近期死亡的预测因子,galectin-3>21.90 ng/mL且sST2>45.03 ng/mL患者生存时间更短。 结论 血清galectin-3、sST2水平与NYHA心功能分级呈低度正相关,在一定程度上可反映心衰患者心功能状态。血清sST2水平对预测患者的预后(死亡、心衰恶化或未发生心脏事件),galectin-3水平对预测心衰患者心脏事件发生,以及两者联合检测对心衰诊断及预后评估有一定的辅助参考价值。

关键词: 慢性心力衰竭, 可溶性肿瘤因子2抑制剂, 半乳糖凝集素-3, 心功能分级, 心衰预后

Abstract: Objective To investigate the value of soluble suppression of tumorigenicity 2(sST2)and galectin-3(Gal-3)in heart failure grading and prognosis by evaluating their levels according to New York Heart Association(NYHA)classification. Methods A total of 191 patients with chronic heart failure treated during Apr. 2015 and Jan. 2016 were chosen randomly, including 115 males and 76 females, average(62.36±11.09)years. According to the NYHA criteria and follow-up results, the patients were classified into three groups: non-cardiac events group, rehospitalization group 山 东 大 学 学 报 (医 学 版)57卷1期 -米传晓,等.血清可溶性肿瘤因子2抑制剂、半乳糖凝集素-3蛋白水平在慢性心衰分级及预后中的应用 \=-and death group. Plasma sST2 and Gal-3 levels were measured at admission and every 2 months during follow-up. The incidence of cardiac events were recorded. Results The levels of sST2 and Gal-3 were positively correlated with NYHA classification(r1=0.33, P1<0.001; r2=0.21, P2=0.004), and negatively correlated with left ventricular ejection fraction(LVEF)(r1=-0.25, P1=0.001; r2=-0.24, P2=0.002). There were significant differences in sST2 and Gal-3 levels among the three groups (F1=56.76, P1<0.001; F2=31.08, P2<0.001). The level of sST2 was significantly different between the non-cardiac events group and rehospitalization group, between the non-cardiac events group and death group, and between the rehospitalization group and death group(t1=6.15, P1<0.001; t2=11.36, P2<0.001; t3=3.22, P3=0.003). The level of Gal-3 was significantly different between the non-cardiac events group and rehospitalization group, and between the non-cardiac events group and death group(t1=6.28, P1<0.001; t2=5.91, P2<0.001). Gal-3<15.67 ng/mL and sST2< 31.74 ng/mL were the predictive factors of non-cardiac events. sST2>45.031 ng/mL was a predictive factor of recent mortality. Gal-3>21.90 ng/mL and sST2>45.03ng/mL were predictors of shortened survival. Conclusion The levels of Gal-3 and sST2 are somewhat positively correlated with NYHA classification, and can indicate the cardiac function of patients with heart failure. The sST2 level is useful to predict patients' prognosis, including death, rehospitalization or non-cardiac events, while Gal-3 level is useful to predict cardiac events. The combined detection of them is valuable for the diagnosis and prognosis of heart failure.

Key words: Chronic heart failure, Soluble suppression of tumorigenicity 2, Galectin-3, Heart function classification, Prognosis

中图分类号: 

  • R541.6
[1] Mosterd A. Clinical epidemiology of heart failure[J]. Heart(British Cardiac Society), 2007, 93(9): 1137-1146.
[2] King M, Kingery J. Diagnosis and evaluation of heart failure[J]. Am Fam Physician, 2012, 85(12): 1161-1168.
[3] McMurray JJ. Clinical practice. Systolic heart failure[J]. N Engl J Med, 2010, 362(3): 228-238.
[4] Krum H, Teerlink JR. Medical therapy for chronic heart failure[J]. Lancet, 2011, 378(9792): 713-721.
[5] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012[J]. Turk Kardiyol Dern Ars, 2012, 40(Suppl 3): 77-137.
[6] Demissei BG, Cotter G, Prescott MF, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial[J]. Eur J Heart Fail, 2017, 19(8): 1001-1010.
[7] Lala RI, Lungeanu D, Darabantiu D, et al. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure[J]. Herz, 2018, 43(2): 146-155.
[8] Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor[J]. FEBS Lett, 1989, 258(2): 301-304.
[9] Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J]. Immunity, 2005, 23(5): 479-490.
[10] Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2,an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction[J]. Circulation, 2002, 106(23): 2961-2966.
[11] Januzzi JL, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE(Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department)study[J]. J Am Coll Cardiol, 2007, 50(7): 607-613.
[12] Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure[J]. Circ Heart Fail, 2011, 4(2): 180-187.
[13] Bayes-Genis A, de Antonio M, Galán A, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure[J]. Eur J Heart Fail, 2012, 14(1): 32-38.
[14] Vorovich E, French B, Ky B, et al. Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis[J]. J Card Fail, 2014, 20(8): 569-576.
[15] Yancy CW, Jessup M, Bozkurt B, et al. 2013ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 62(16):147-239.
[16] Liu FT, Hsu DK, Zuberi RI, et al. Expression and function of Galectin-3,a beta-galactoside-binding lectin, in human monocytes and macrophages[J]. Am J Pathol, 1995, 147(4): 1016-1028.
[17] Carrasco FJ, Aramburu O, Salamanca P, et al. Predictive value of serum Galectin-3 levels in patients with acute heart failure with preserved ejection fraction[J]. Int J Cardiol, 2013, 169(3): 177-182.
[18] Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction[J]. Circulation, 2004, 110(19): 3121-3128.
[19] Lin YH, Lin LY, Wu YW, et al. The relationship between serum Galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients[J]. Clin Chim Acta, 2009, 409(1-2): 96-99.
[20] Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of Galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study[J]. Clin Res Cardiol, 2010, 99(5): 323-328.
[21] Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3[J]. J Am Coll Cardiol, 2014, 63(2): 158-166.
[22] Ky B, French B, Levy WC, et al. Multiple biomarkers for risk prediction in chronic heart failure[J]. Circ Heart Fail, 2012, 5(2): 183-190.
[23] Lupón J, de Antonio M, Galán A, et al. Combined use of the novel high sensitivity of troponin biomarkers and ST2 for risk stratification heart failure vs conventional assessment[J]. Mayo Clin Proc, 2013, 88(3): 234-243.
[24] Wojtczak-Soska K, Sakowicz A, Pietrucha T, et al. Soluble ST2 protein in the short-term prognosis after hospitalization in chronic systolic heart failure[J]. Kardiol Pol, 2014, 72(8): 725-734.
[25] Gruson D, Ferracin B, Ahn SA, et al. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients[J]. Int J Cardiol, 2015,189:185-187. doi: org/10.1016/j.ijcard.2015.04.074.
[26] Piper SE, Sherwood RA, Amin-Youssef GF, et al. Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure[J]. Int J Cardiol, 2015, 178: 284-291. doi: org/10.1016/j.ijcard.2014.11.097.
[27] Miller WL, Saenger AK, Grill DE, et al. Prognostic value of serial measurements of soluble suppression of tumorigenicity 2 and galectin-3 in ambulatory patients with chronic heart failure[J]. J Card Fail, 2016, 22(4): 249-255.
[1] 兰洪涛,贾旭,童洲杰,郑曼,胡伯昂,钟明,张薇,王志浩. 无选择性152例成年慢性心力衰竭患者再入院的危险因素[J]. 山东大学学报 (医学版), 2021, 59(4): 63-69.
[2] 尹黎波, 李慧萍. 曲美他嗪治疗重症疾患并发 慢性心力衰竭患者的临床疗效[J]. 山东大学学报（医学版）, 2014, 52(S2): 99-100.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发